TiumBio Co., Ltd.

KOSDAQ:A321550 Stock Report

Market Cap: ₩167.6b

TiumBio Valuation

Is A321550 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A321550 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A321550's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A321550's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A321550?

Other financial metrics that can be useful for relative valuation.

A321550 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue23.3x
Enterprise Value/EBITDA-11.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does A321550's PS Ratio compare to its peers?

The above table shows the PS ratio for A321550 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average20.7x
A317690 QuantaMatrix
44.1xn/a₩159.1b
A115180 Qurient
17.7xn/a₩155.0b
A226950 OliX Pharmaceuticals
16.4xn/a₩294.2b
A314130 Genome
4.4xn/a₩105.6b
A321550 TiumBio
21.2xn/a₩167.6b

Price-To-Sales vs Peers: A321550 is expensive based on its Price-To-Sales Ratio (21.2x) compared to the peer average (20.7x).


Price to Earnings Ratio vs Industry

How does A321550's PE Ratio compare vs other companies in the KR Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a64.9%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a64.9%
n/an/an/a
No more companies

Price-To-Sales vs Industry: A321550 is expensive based on its Price-To-Sales Ratio (21.2x) compared to the KR Biotechs industry average (9x).


Price to Sales Ratio vs Fair Ratio

What is A321550's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A321550 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio21.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A321550's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies